Prevalence of transmitted HIV-1 drug resistance in Tel-Aviv, Israel, from 2010-2013

The prevalence of transmitted drug resistance mutations (TDR) was assessed in treatmentnaive patients in Tel-Aviv. All HIV patients from our clinic were considered as potential transmitters (PT). Antiretroviral (ARV) use and treatment failure (TF) was evaluated. All blood samples obtained from treat...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2014-01, Vol.19, p.A67-A67
Main Authors: Turner, D, Finn, T, Matos, N, Zeldis, I, Tellio, H, Chalom, S, Parti, I, Katchman, E, Alon, D, Yust, I, Hassin, D, Avidor, B
Format: Article
Language:English
Subjects:
Human immunodeficiency virus 1
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prevalence of transmitted drug resistance mutations (TDR) was assessed in treatmentnaive patients in Tel-Aviv. All HIV patients from our clinic were considered as potential transmitters (PT). Antiretroviral (ARV) use and treatment failure (TF) was evaluated. All blood samples obtained from treatmentnaive patients between 2010 and 2013 were analyzed for RT and PR resistance associated mutations. TDR were defined according to the 2009 criteria of Bennett et al. 27 samples from 2013 were assessed for integrase inhibitor (InI) resistance mutations. A phylogeny was inferred using pol sequences. There was a drop in TDR between 2011 and 2013 among patients followed in Tel-Aviv. Although the number of samples tested for InI was small, the rate of TDR for these drugs is reportedly low. The lowering of TDR could correspond to a change in antiretroviral strategy and lower TF rates among PT treated patients. Long-term follow-up is needed to assess the rate of TDR in the era of new strategies and ARV.
ISSN:1359-6535